Table 2.

Demographics of fungal infections in ECMO patients, separated by timing of infection and fungal species. Fungal species are designated as Candida or non-Candida species. For each subgroup, the specific prevalence and associated patient mortality is shown. Univariate analysis of mortality between fungal species groups within each age group demonstrated no significant differences with p > 0.05.

Neonates	Candida Sp	Non-Candida Sp	p value
Prevalence of Pre-ECMO Infection	91.2% (31)	8.8% (3)
Mortality of Patients with Pre-ECMO Infection	61% (19/31)	33% (1/3)	0.3475
Prevalence of On-ECMO Infection	84% (99)	16% (19)
Mortality of Patients with On-ECMO Infection	70% (69/99)	89% (17/19)	0.0757
Pediatrics	Candida Sp	Non-Candida Sp	p value
Prevalence of Pre-ECMO Infection	92% (52)	8% (6)
Mortality of Patients with Pre-ECMO Infection	69% (36/52)	50% (3/6)	0.3419
Prevalence of On-ECMO Infection	84% (145)	16% (28)
Mortality of Patients with On-ECMO Infection	58% (84/145)	57% (16/28)	0.9384
Adults	Candida Sp	Non-Candida Sp	p value
Prevalence of Pre-ECMO Infection	82% (27)	18% (6)
Mortality of Patients with Pre-ECMO Infection	81% (22/27)	67% (4/6)	0.4220
Prevalence of On-ECMO Infection	81% (86)	19% (20)
Mortality of Patients with On-ECMO Infection	50% (43/86)	35% (7/20)	0.2261